30 April 2024 - Neurocrine Biosciences today announced the US FDA has approved Ingrezza Sprinkle (valbenazine) capsules, a new oral granules formulation of Ingrezza (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease.

Ingrezza Sprinkle provides an alternative administration option for those who experience dysphagia or have difficulty swallowing.

Read Neurocrine Biosciences press release